INSULIN GLARGINE YFGN

N/A

Manufactured by Biocon Biologics Inc.

39,886 FDA adverse event reports analyzed

Last updated: 2026-04-14

About INSULIN GLARGINE YFGN

INSULIN GLARGINE YFGN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Biocon Biologics Inc.. The most commonly reported adverse reactions for INSULIN GLARGINE YFGN include HYPOGLYCAEMIA, BLOOD GLUCOSE INCREASED, ACUTE KIDNEY INJURY, DYSPNOEA, HYPERGLYCAEMIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for INSULIN GLARGINE YFGN.

Top Adverse Reactions

HYPOGLYCAEMIA1,542 reports
BLOOD GLUCOSE INCREASED1,484 reports
ACUTE KIDNEY INJURY950 reports
DYSPNOEA940 reports
HYPERGLYCAEMIA889 reports
NAUSEA885 reports
DIARRHOEA839 reports
DRUG INEFFECTIVE838 reports
VOMITING777 reports
FATIGUE757 reports
OFF LABEL USE754 reports
CONDITION AGGRAVATED734 reports
DIZZINESS633 reports
ASTHENIA630 reports
FALL630 reports
DRUG INTERACTION579 reports
PNEUMONIA565 reports
HYPOTENSION558 reports
PYREXIA552 reports
MALAISE549 reports
PAIN IN EXTREMITY529 reports
ANAEMIA492 reports
HEADACHE491 reports
DIABETES MELLITUS INADEQUATE CONTROL488 reports
PAIN481 reports
WEIGHT DECREASED466 reports
DEHYDRATION448 reports
DIABETIC KETOACIDOSIS443 reports
LACTIC ACIDOSIS441 reports
BLOOD GLUCOSE DECREASED428 reports
DEATH427 reports
GENERAL PHYSICAL HEALTH DETERIORATION421 reports
DECREASED APPETITE419 reports
ABDOMINAL PAIN418 reports
GLYCOSYLATED HAEMOGLOBIN INCREASED416 reports
HYPERTENSION412 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION405 reports
RENAL FAILURE389 reports
RENAL IMPAIRMENT385 reports
ANXIETY372 reports
CONFUSIONAL STATE370 reports
ARTHRALGIA366 reports
CEREBROVASCULAR ACCIDENT365 reports
TOXICITY TO VARIOUS AGENTS358 reports
URINARY TRACT INFECTION357 reports
MYOCARDIAL INFARCTION350 reports
WEIGHT INCREASED325 reports
VISUAL IMPAIRMENT313 reports
COUGH311 reports
HYPERHIDROSIS310 reports
SEPSIS309 reports
CHEST PAIN306 reports
OEDEMA PERIPHERAL298 reports
LOSS OF CONSCIOUSNESS296 reports
DEVICE MECHANICAL ISSUE295 reports
HYPERKALAEMIA292 reports
PRURITUS276 reports
RASH274 reports
ABDOMINAL PAIN UPPER265 reports
BLOOD GLUCOSE FLUCTUATION263 reports
GAIT DISTURBANCE261 reports
CONSTIPATION258 reports
COVID 19256 reports
PERIPHERAL SWELLING254 reports
RESPIRATORY FAILURE254 reports
PRODUCT DOSE OMISSION245 reports
SOMNOLENCE245 reports
TREMOR237 reports
BACK PAIN236 reports
ASTHMA233 reports
ATRIAL FIBRILLATION232 reports
OVERDOSE230 reports
LUNG DISORDER227 reports
VASCULITIS227 reports
TACHYCARDIA225 reports
MUSCULAR WEAKNESS222 reports
SYNCOPE221 reports
MEMORY IMPAIRMENT217 reports
BLOOD GLUCOSE ABNORMAL213 reports
FEELING ABNORMAL212 reports
HYPONATRAEMIA212 reports
HYPOTHYROIDISM212 reports
HAEMOPTYSIS209 reports
THERAPEUTIC PRODUCT EFFECT INCOMPLETE209 reports
HYPOXIA207 reports
WHEEZING207 reports
BLOOD CREATININE INCREASED206 reports
INTENTIONAL PRODUCT MISUSE202 reports
PRODUCT USE ISSUE202 reports
PRODUCT STORAGE ERROR201 reports
METABOLIC ACIDOSIS200 reports
PULMONARY FIBROSIS198 reports
BRADYCARDIA197 reports
CARDIAC FAILURE197 reports
CATARACT195 reports
INSOMNIA195 reports
OBSTRUCTIVE AIRWAYS DISORDER195 reports
THROMBOCYTOPENIA195 reports
PULMONARY EMBOLISM194 reports
CHRONIC KIDNEY DISEASE193 reports

Report Outcomes

Out of 20,578 classified reports for INSULIN GLARGINE YFGN:

Serious 88.2%Non-Serious 11.8%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male9,919 (52.6%)
Female8,907 (47.2%)
Unknown30 (0.2%)

Reports by Age

Age 65629 reports
Age 70508 reports
Age 73498 reports
Age 72496 reports
Age 69490 reports
Age 68468 reports
Age 62467 reports
Age 71457 reports
Age 63440 reports
Age 64439 reports
Age 76434 reports
Age 74430 reports
Age 66405 reports
Age 56402 reports
Age 67402 reports
Age 75401 reports
Age 60387 reports
Age 77374 reports
Age 61372 reports
Age 55365 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with INSULIN GLARGINE YFGN?

This profile reflects 39,886 FDA FAERS reports that mention INSULIN GLARGINE YFGN. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for INSULIN GLARGINE YFGN?

Frequently reported terms in FAERS include HYPOGLYCAEMIA, BLOOD GLUCOSE INCREASED, ACUTE KIDNEY INJURY, DYSPNOEA, HYPERGLYCAEMIA, NAUSEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures INSULIN GLARGINE YFGN?

Labeling and FAERS entries often list Biocon Biologics Inc. in connection with INSULIN GLARGINE YFGN. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.